Clinical Trial Update: MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of MGD007 combined with MGA012 for relapsed/refractory metastatic colorectal cancer completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MGA012 (MGA012)
• MGD007 (MGD007)

Snippet

Sponsor: MacroGenics | Conditions: Colorectal Cancer Metastatic | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-11-10